IBDEI0J4 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8977,0)
 ;;=253.5^^38^507^3
 ;;^UTILITY(U,$J,358.3,8977,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8977,1,4,0)
 ;;=4^DIABETES INSIPIDUS
 ;;^UTILITY(U,$J,358.3,8977,1,5,0)
 ;;=5^253.5
 ;;^UTILITY(U,$J,358.3,8977,2)
 ;;=^33572
 ;;^UTILITY(U,$J,358.3,8978,0)
 ;;=253.8^^38^507^4
 ;;^UTILITY(U,$J,358.3,8978,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8978,1,4,0)
 ;;=4^EMPTY SELLA SYNDROME
 ;;^UTILITY(U,$J,358.3,8978,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,8978,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,8979,0)
 ;;=253.1^^38^507^5
 ;;^UTILITY(U,$J,358.3,8979,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8979,1,4,0)
 ;;=4^HYPERPROLACTINEMIA
 ;;^UTILITY(U,$J,358.3,8979,1,5,0)
 ;;=5^253.1
 ;;^UTILITY(U,$J,358.3,8979,2)
 ;;=^87260
 ;;^UTILITY(U,$J,358.3,8980,0)
 ;;=253.2^^38^507^6
 ;;^UTILITY(U,$J,358.3,8980,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8980,1,4,0)
 ;;=4^PANHYPOPITUITARISM
 ;;^UTILITY(U,$J,358.3,8980,1,5,0)
 ;;=5^253.2
 ;;^UTILITY(U,$J,358.3,8980,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,8981,0)
 ;;=227.3^^38^507^8
 ;;^UTILITY(U,$J,358.3,8981,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8981,1,4,0)
 ;;=4^PITUITARY TUMOR,BENIGN
 ;;^UTILITY(U,$J,358.3,8981,1,5,0)
 ;;=5^227.3
 ;;^UTILITY(U,$J,358.3,8981,2)
 ;;=^267690
 ;;^UTILITY(U,$J,358.3,8982,0)
 ;;=253.8^^38^507^9
 ;;^UTILITY(U,$J,358.3,8982,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8982,1,4,0)
 ;;=4^RATHKE'S CYST
 ;;^UTILITY(U,$J,358.3,8982,1,5,0)
 ;;=5^253.8
 ;;^UTILITY(U,$J,358.3,8982,2)
 ;;=^87533
 ;;^UTILITY(U,$J,358.3,8983,0)
 ;;=239.7^^38^507^7
 ;;^UTILITY(U,$J,358.3,8983,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8983,1,4,0)
 ;;=4^PITUITARY TUMOR
 ;;^UTILITY(U,$J,358.3,8983,1,5,0)
 ;;=5^239.7
 ;;^UTILITY(U,$J,358.3,8983,2)
 ;;=^267785
 ;;^UTILITY(U,$J,358.3,8984,0)
 ;;=253.4^^38^508^3
 ;;^UTILITY(U,$J,358.3,8984,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8984,1,4,0)
 ;;=4^ANTER PITUITARY DIS NEC
 ;;^UTILITY(U,$J,358.3,8984,1,5,0)
 ;;=5^253.4
 ;;^UTILITY(U,$J,358.3,8984,2)
 ;;=^267862
 ;;^UTILITY(U,$J,358.3,8985,0)
 ;;=258.9^^38^508^17
 ;;^UTILITY(U,$J,358.3,8985,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8985,1,4,0)
 ;;=4^POLYGLANDUL DYSFUNC NOS
 ;;^UTILITY(U,$J,358.3,8985,1,5,0)
 ;;=5^258.9
 ;;^UTILITY(U,$J,358.3,8985,2)
 ;;=^267894
 ;;^UTILITY(U,$J,358.3,8986,0)
 ;;=258.1^^38^508^18
 ;;^UTILITY(U,$J,358.3,8986,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8986,1,4,0)
 ;;=4^POLYGLANDULAR FAILURE
 ;;^UTILITY(U,$J,358.3,8986,1,5,0)
 ;;=5^258.1
 ;;^UTILITY(U,$J,358.3,8986,2)
 ;;=^267892
 ;;^UTILITY(U,$J,358.3,8987,0)
 ;;=626.0^^38^508^1
 ;;^UTILITY(U,$J,358.3,8987,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8987,1,4,0)
 ;;=4^AMENORRHEA
 ;;^UTILITY(U,$J,358.3,8987,1,5,0)
 ;;=5^626.0
 ;;^UTILITY(U,$J,358.3,8987,2)
 ;;=^5871
 ;;^UTILITY(U,$J,358.3,8988,0)
 ;;=628.0^^38^508^2
 ;;^UTILITY(U,$J,358.3,8988,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8988,1,4,0)
 ;;=4^ANOVULATION,INFERTILITY
 ;;^UTILITY(U,$J,358.3,8988,1,5,0)
 ;;=5^628.0
 ;;^UTILITY(U,$J,358.3,8988,2)
 ;;=^270583
 ;;^UTILITY(U,$J,358.3,8989,0)
 ;;=626.5^^38^508^15
 ;;^UTILITY(U,$J,358.3,8989,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8989,1,4,0)
 ;;=4^OVULATION BLEEDING
 ;;^UTILITY(U,$J,358.3,8989,1,5,0)
 ;;=5^626.5
 ;;^UTILITY(U,$J,358.3,8989,2)
 ;;=^270570
 ;;^UTILITY(U,$J,358.3,8990,0)
 ;;=627.1^^38^508^19
 ;;^UTILITY(U,$J,358.3,8990,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8990,1,4,0)
 ;;=4^POSTMENOPAUSAL BLEEDING
 ;;^UTILITY(U,$J,358.3,8990,1,5,0)
 ;;=5^627.1
 ;;^UTILITY(U,$J,358.3,8990,2)
 ;;=^97040
 ;;^UTILITY(U,$J,358.3,8991,0)
 ;;=617.9^^38^508^5
 ;;
 ;;$END ROU IBDEI0J4
